Using data from NIH Research Portfolio Online Reporting Tools (RePORT) and recently assembled prevalence estimates of 6 major neurologic diseases, we compared the relative prevalences and the annual NIH support levels for 6 major neurologic disorders: Alzheimer disease, amyotrophic lateral sclerosis (ALS), epilepsy, multiple sclerosis, Parkinson disease, and stroke. Compared to these other major neurologic disorders, epilepsy research is funded at a persistently lower rate based on relative disease prevalences. Relative NIH funding for these other disorders in 2010 adjusted for prevalence ranged from 1.7x (stroke) to 61.1x (ALS) greater than epilepsy. The disparity cannot be explained by differences in the overall impact of these diseases on US citizens. Greater transparency in the review and funding process is needed to disclose the reason for this disparity. Neurology ® 2011;77:1305-1307 GLOSSARY AD ϭ Alzheimer disease; ALS ϭ amyotrophic lateral sclerosis; MS ϭ multiple sclerosis; NINDS ϭ National Institute of Neurological Disorders and Stroke; PD ϭ Parkinson disease; RePORT ϭ Research Portfolio Online Reporting Tools.
funding was listed in the NIH RePORT 2 with reliable estimate for the number of cases in each disease category across the lifespan in the United States. 3 Because accurate prevalence estimates could not be established for several disorders reported (i.e., traumatic brain injury, spinal cord injury, and Tourette syndrome) and because prevalence estimates were available only for individuals under 21 years of age for some disorders (i.e., autism spectrum disorders and cerebral palsy), those conditions were not included in this analysis. Similarly, migraine was not included because it is not listed individually in the NIH RePORT. 2
RESULTS
Based on the data (table), stroke is the most common neurologic disease, followed by AD and epilepsy, all of which have between 2 and 3 million sufferers. The 3 remaining conditions, MS, PD, and ALS, are far less prevalent, with between 12,000 (ALS) and 350,000 (PD) sufferers. Current NIH spending appears commensurate for stroke and AD, which have the highest level of NIH funding. In contrast, epilepsy, the third most prevalent condition, obtains less funding than all but one condition (ALS), and has approximately equivalent funding as 2 conditions that are approximately 1/6 as prevalent. Overall, the funding disparity for epilepsy has worsened since 2007.
DISCUSSION
The data demonstrate a persistently lower funding of epilepsy compared to other major neurologic disorders based on their relative prevalences. Further, the situation for epilepsy has deteriorated since 2007. The NIH does not expressly budget by category, and annual estimates reflect change as a result of science, actual research projects funded, and the NIH budget. The reason for lower funding of epilepsy cannot be due to relative prevalence (table) . The mortality of ALS and the increasing prevalence of AD could influence their relative funding. In contrast, lower funding for epilepsy may relate to the fact that approximately 2/3 of persons with epilepsy achieve reasonable seizure control. Even with this consideration, the prevalence of treatment-resistant epilepsy is double that of MS and PD. Epilepsy has a high mortality and morbidity, 4 -13 which is at least comparable to the other neurologic disorders. In addition, epilepsy has a higher incidence in children than these other disorders, which arguably leads to greater disease burden due to cumulative effects across the lifespan.
Since the disparity in funding for epilepsy is not due to lower prevalence, mortality, or morbidity, what may account for it? Factors that might potentially contribute to the lower NIH funding could include the processes of review and funding: 1) a consistently poorer scientific quality of epilepsy grant proposals, 2) inequality in epilepsy representation and expertise on the NIH review panels in a process that pits one disease against another, 3) allocation of funding by Congress, 4) more effective lobby activities to promote research funding for the other diseases, and 5) a poorer, more disadvantaged patient population. The contribution of these or other possible factors is unclear. Thus, the cause remains uncertain. Our governmental funding for medical research should be allocated based on the impact of diseases on US citizens. This becomes increasingly important during periods of budgetary restraint. Funding for biomedical research should not be left to imprecise processes. There should be a direct link between the impact of disease on the US population and relative funding for research by the government. Further, funding and its effects should be closely monitored so that adjustments can be made to maximize application of available funds. When funding disparities exist across diseases, the reasons should be transparent. Unfortunately, the present funding disparity means that patients with epilepsy will have less opportunity for research to alleviate their suffering and that they are more likely to continue to have increased rates of death, 4-6 injury, 7 cognitive impairment, 8, 9 depression, 10 suicidality, 11 psychosocial isolation, 12 unemployment, 12 and impaired quality of life. 13 
